

Announcement no. 9/2015
To NASDAQ Copenhagen

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

8 October 2015

Major shareholder announcement

Exiqon A/S, listed on NASDAQ Copenhagen (“EXQ”), has been informed by Teknoinvest VIII KS with its registered office at Smalgangen 3, 0188 Oslo, Norway (Reg. No. 984 641 516), that after a sale of shares they now hold 1,824,000 shares corresponding to 4.95% of the share capital and voting rights in Exiqon A/S.

Additional information

Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, phone +45 4566 0888 (cell: +45 4090 2131)

About Exiqon

Exiqon operates in two business areas: Exiqon Life Sciences, a leading provider of flexible solutions for RNA analysis. Exiqon’s research products are used by academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of cancer and other diseases. Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to develop novel molecular diagnostic tests for early detection of diseases, which can help physicians make treatment decisions based on the tools developed by Exiqon Life Sciences. Exiqon is listed on NASDAQ in Copenhagen. For more information about us, please visit www.exiqon.com

